Solid Biosciences
CHARLESTOWN, MA · CIK 0001707502 · Biotech · Public
Gene therapy candidates for rare neuromuscular and cardiac diseases
solidbio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $109M
- 3 Form D · Dec 2022
- 46 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 1 granted · 39 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $59,977,035 | |
| Private capital raised | Form D · SEC | $39,999,996 | |
| Private capital raised | Form D · SEC | $9,200,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2842 | EXPRESSION THERAPEUTICS, LLC | — | — |
| 2843 | CinCor Pharma | — | $143M |
| 2844 | GRADIENT BIOMODELING, LLC | — | — |
| 2845 | Solid Biosciences | — | $109M |
| 2846 | Lomond Therapeutics | — | — |
| 2847 | Cardurion Pharmaceuticals | — | $350M |
| 2848 | DIGITAL NANOGENETICS, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Alvaro AmorrortuExecutive Officer
- Matthew ArnoldDirector
- Alexander (Bo) CumboDirector · Executive Officer
- Stephen DiPalmaExecutive Officer
- Martin FreedDirector
- Ilan GanotDirector · Executive Officer
- Jessie HanrahanExecutive Officer
- Paul HerizchExecutive Officer
- Lynette HerschaExecutive Officer
- David HowtonExecutive Officer
- Robert HuffinesDirector
- Clare KahnDirector
- Georgia KerestyDirector
- Adam KoppelDirector
- Jennifer MarloweExecutive Officer
- Carl MorrisExecutive Officer
- Sukumar NagendranDirector
- Jorge QuirozExecutive Officer
- Joel SchneiderExecutive Officer
- Rajeev ShahDirector
- Ian SmithDirector
- Adam StoneDirector
- Lynne SullivanDirector
- Andrey ZarurDirector
- Jennifer ZiolkowskiExecutive Officer
Patents
- Modified Aav Capsids And Uses Thereofgranted
- Treatment Of Muscular Dystrophyapplication
- Recombinant Herpesvirales Vectorapplication
- Viral Vector For Combination Therapyapplication
- Recombinant Herpesvirales Vectorapplication
- Combination Therapy For Treating Muscular Dystrophyapplication
- Recombinant Aav Production Processapplication
- Low Dose Aav Administrationapplication
- Method Of Aav Productionapplication
- Methods And Constructs For Increasing Solid Organ Transplant Survivalapplication
- AAV gene therapy with reduced adverse events and enhanced functionapplication
- Methods And Compositions For Evaluating And Treating Muscular Disordersapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.